UK's NICE to Issue Guidance on Herceptin This Week

LONDON (Reuters Health) Mar 13 – Britain's National Institute for Clinical Excellence has said it plans to issue guidance on Roche and Genentech's breast cancer therapy Herceptin (trastuzumab) on Friday.
Last week, the cost effectiveness watchdog issued a statement rejecting routine use of three new drugs for bowel cancer. This time, however, it is organising a press conference, which suggests it may recommend Herceptin.


0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים